Experiences with
Venetoclax1,059 public posts
Want to take advantage of all our features? Just log in!
or
Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLL
the rationale behind the use of venetoclax as a retreatment for CLL/SLL.
How you can help make ibrutinib plus venetoclax fixed duration therapy a reality for Australians with previously untreated CLL
In March 2024, PBAC will again consider a submission to recommend a 15-month combination therapy of ibrutinib plus venetoclax for those with untreated CLL.